Enoxaparin in ACS

More documents

Recommendations

Info

%1098765432104.8%INTERACT(Aspirin + Integrilin)UHEnoxaparinP = 0.03031.8%MB 96 hrs25.4%P = 0.030314.3%Death/MI 30dNICE - 3NationalInvestigatorsCollaborating on Enoxaparin
NICE -3Objectiveso To assess the safety yp profile (primarily withrespect to bleeding) of enoxaparin and a IIb/IIIaantagonist (abciximab, eptifibatide or tirofiban) inpatients with ACSo To assess the feasibility and safety of bringingpatients t forward to the catheterization t ti laboratoryon combination therapy (without the use of UFheparin)NICE -3Protocol661 patients enrolledAll treated t withEnoxaparin46 clinical sites inUS / CanadaStudy Initiatedt January 2000[Enoxaparinalone](n=45)Tirofiban(n=217)Eptifibatide(n=252)All IIb/IIIa patients(n=616)Abciximab(n=147)Enrollment CompletedMay 2000In-hospital, 14-day, and 30-day follow-upData availableAugust 2000
Page 1 and 2: Enoxaparin in ACSWhen evidence meet
Page 3 and 4: o DefinitionsAgendao Is UFH w/o dis
Page 5 and 6: Superiority ofEnoxaparin over UFHEv
Page 7 and 8: Coronary patency (TIMI flow 2 or 3)
Page 9 and 10: Enoxaparin versus UFH for STEMIOne
Page 11 and 12: No Increase in ICHents% Ev10UFHENOX
Page 13 and 14: New Data from ExTRACT-TIMI 251YEAR
Page 15 and 16: Net Clinical BenefitDeath/MI/Disabl
Page 17 and 18: Summary-23. Net clinical benefit si
Page 19: Enoxaparin and GP IIb/IIIa inhibito
Page 23 and 24: o DefinitionsAgendao Is UFH w/o dis
Page 25 and 26: Clexane in ACS - My ApproachACSCons
Page 27: Egyptian Guidelines for themanageme

Enoxaparin in ACS

Create successful ePaper yourself

Delete template?

Save as template?